Assignee
CAMURUS AB
SE·23 granted patents·34 pending applications·102 citations·filing 1987–2025
Top patents by PatentIndex Score
57 records- 0196US11135215B2Opioid formulationsCAMURUS AB·Filed 2021·Granted Oct 5, 2021·3 cites·30 claims
- 0296US10912772B2Opioid formulationsCAMURUS AB·Filed 2020·Granted Feb 9, 2021·4 cites·16 claims
- 0395US11135264B2Formulations containing a somatostatin receptor agonistCAMURUS AB·Filed 2020·Granted Oct 5, 2021·3 cites·32 claims
- 0494US12161640B2Opioid formulationsCAMURUS AB·Filed 2023·Granted Dec 10, 2024·1 cites·10 claims
- 0594US11110084B2Opioid formulationsCAMURUS AB·Filed 2021·Granted Sep 7, 2021·2 cites·30 claims
- 0694US10688148B2Formulations containing a somatostatin receptor agonistCAMURUS AB·Filed 2019·Granted Jun 23, 2020·7 cites·49 claims
- 0791US9585959B2Robust controlled-release formulationsCAMURUS AB·Filed 2012·Granted Mar 7, 2017·16 cites·34 claims
- 0891US2025281407A1Lipid depot formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 0990US11564968B2Formulations containing a somatostatin receptor agonistCAMURUS AB·Filed 2021·Granted Jan 31, 2023·1 cites·31 claims
- 1090US9526788B2Pharmaceutical lipid compositionsCAMURUS AB·Filed 2015·Granted Dec 27, 2016·8 cites·25 claims
- 1188US12029813B2Injectable buprenorphine formulationCAMURUS AB·Filed 2021·Granted Jul 9, 2024·1 cites·22 claims
- 1287US12396944B2Injectable buprenorphine formulationCAMURUS AB·Filed 2024·Granted Aug 26, 2025·0 cites·20 claims
- 1387US12318379B2Opioid formulationsCAMURUS AB·Filed 2024·Granted Jun 3, 2025·0 cites·10 claims
- 1487US9937164B2Opioid formulationsCAMURUS AB·Filed 2013·Granted Apr 10, 2018·7 cites·28 claims
- 1586US9649382B2Topical bioadhesive formulationsCAMURUS AB·Filed 2013·Granted May 16, 2017·5 cites·23 claims
- 1686US2025000982A1Peptide slow-release formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 1785US11241476B2Mixtures and formulations comprising an alkyl ammonium EDTA saltCAMURUS AB·Filed 2017·Granted Feb 8, 2022·1 cites·24 claims
- 1883US9968680B2Topical bioadhesive formulationsCAMURUS AB·Filed 2014·Granted May 15, 2018·5 cites·29 claims
- 1983US9555118B2Robust controlled-release peptide formulationsCAMURUS AB·Filed 2012·Granted Jan 31, 2017·5 cites·36 claims
- 2082US2023027339A1Lipid depot formulationsCAMURUS AB·Filed 2022·Application pending·0 cites
- 2181US2025319097A1Prostacyclin analogue formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 2281US2025121035A1Controlled release peptide formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 2380US12257282B2Mixtures and formulationsCAMURUS AB·Filed 2022·Granted Mar 25, 2025·0 cites·38 claims
- 2479US11672843B2Somatostatin receptor agonist formulationsCAMURUS AB·Filed 2013·Granted Jun 13, 2023·1 cites·29 claims
- 2577US2023372436A1Somatostatin receptor agonist formulationsCAMURUS AB·Filed 2023·Application pending·0 cites
- 2676US2026097031A1Opioid formulationsCAMURUS AB·Filed 2025·Application pending·0 cites
- 2776US2025345385A1Mixtures and formulations comprising an alkyl ammonium edta saltCAMURUS AB·Filed 2025·Application pending·0 cites
- 2874US2021128473A1Lipid depot formulationsCAMURUS AB·Filed 2020·Application pending·0 cites
- 2973US2021268112A1Peptide slow-release formulationsCAMURUS AB·Filed 2021·Application pending·0 cites
- 3073US2022387445A1Prostacyclin analogue formulationsCAMURUS AB·Filed 2022·Application pending·0 cites
- 3169US2021308226A1Controlled release peptide formulationsCAMURUS AB·Filed 2021·Application pending·0 cites
- 3268US2018311163A1Lipid depot formulationsCAMURUS AB·Filed 2018·Application pending·0 cites
- 3367US2026000730A1Somatostatin receptor agonist formulationsCAMURUS AB·Filed 2025·Application pending·0 cites
- 3467US2015064118A1Lipid depot formulationsCAMURUS AB·Filed 2014·Application pending·0 cites
- 3566US11369617B2Prostacyclin analogue formulationsCAMURUS AB·Filed 2017·Granted Jun 28, 2022·0 cites·31 claims
- 3666US2019350841A1Lipid formulations comprising a thiolated antioxidantCAMURUS AB·Filed 2018·Application pending·0 cites
- 3764US2014193347A1Lipid depot formulationsCAMURUS AB·Filed 2013·Application pending·0 cites
- 3863US2023285502A1Mixtures and formulationsCAMURUS AB·Filed 2023·Application pending·0 cites
- 3962US2019054177A1Peptide slow-release formulationsCAMURUS AB·Filed 2018·Application pending·0 cites
- 4061US5260282ASaliva substituteCAMURUS AB·Filed 1992·Granted Nov 9, 1993·16 cites·25 claims
- 4161US2018250286A1Opioid formulationsCAMURUS AB·Filed 2018·Application pending·0 cites
- 4261US2017281537A1Lipid formulations comprising a thiolated antioxidantCAMURUS AB·Filed 2017·Application pending·0 cites
- 4360US2014219935A1Topical bioadhesive formulationsCAMURUS AB·Filed 2013·Application pending·0 cites
- 4460US2018078647A1Gnrh analogue formulationsCAMURUS AB·Filed 2017·Application pending·0 cites
- 4560US2020353086A1Controlled-release formulationsCAMURUS AB·Filed 2020·Application pending·0 cites
- 4659US2013267585A1Pharmaceutical composition having a cationic excipientCAMURUS AB·Filed 2013·Application pending·0 cites
- 4758US12246055B2Lipid-controlled release compositionsCAMURUS AB·Filed 2020·Granted Mar 11, 2025·0 cites·23 claims
- 4857US2018207089A1Acid containing lipid formulationsCAMURUS AB·Filed 2017·Application pending·0 cites
- 4957US2025325626A1Lipid-controlled release compositionsCAMURUS AB·Filed 2025·Application pending·0 cites
- 5057US2025281569A1Compositions and methods for treating neuroendocrine tumorsCAMURUS AB·Filed 2022·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →